SuperworthAtara Biotherapeutics ATRA
- Market cap
- $86.2M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Atara Biotherapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.1M−52% | $4.3M+1824% | $27.4M+2131% | $28.6M+2893% | $40.2M+1780% | $32.8M+670% | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $56.9M−19% | $49.6M−21% | $45.5M−27% | $33.3M−41% | $43.9M−23% | $28.7M−42% | $27.4M−40% | $7.3M−78% | $2.9M−93% | n/a | $164K−99% | $1.3M−82% |
| SG&A | $12.2M−35% | $11.5M−14% | $11.1M−20% | $8.9M−33% | $10.4M−15% | $9.4M−18% | $11.5M+3% | $6.5M−27% | $4M−62% | n/a | $3.6M−69% | $3.8M−41% |
| −$69.6M−18% | −$60M−21% | −$31.2M−58% | −$18.2M−75% | −$21.8M−69% | −$12.2M−80% | $38.8M | $3.2M | −$3.6M−84% | n/a | −$3.4M | −$4.7M | |
| Interest expense | $1.4M+1034% | $1.2M+905% | $1.2M−14% | $1.3M−8% | $1.2M−15% | $1M−14% | $1M−12% | $972K−23% | $909K−23% | n/a | $830K−18% | $191K−80% |
| Pre-tax income | −$69.8M−17% | −$60.4M−19% | −$31.7M−58% | −$19M−73% | −$21.9M−69% | −$12.7M−79% | $38M | $2.4M | −$4.3M−81% | n/a | −$4.1M | −$4.8M |
| −$19K | $11K+450% | $24K+9% | $0 | −$17K−11% | −$19K | $0 | $3K | $28K | n/a | $0 | $1K−67% | |
| Net income | −$69.8M−17% | −$60.5M−19% | −$31.8M−58% | −$19M−73% | −$21.9M−69% | −$12.7M−79% | $38M | $2.4M | −$4.3M−80% | −$3.4M−73% | −$4.1M | −$4.8M |
| −$16.40−20% | −$13.99−22% | −$5.65−69% | −$3.10−82% | −$2.93−82% | −$1.19−92% | $3.50 | $0.19 | −$0.32−89% | −$0.25−79% | −$0.29 | −$0.32 | |
| 4.3M+4% | 4.3M+5% | 5.6M+35% | 6.1M+46% | 7.5M+75% | 10.7M+147% | 10.9M+93% | 12.3M+100% | 13.6M+82% | 13.6M+27% | 14.1M+30% | 15M+22% |
EPS, diluted: 12 periods, Q4 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Atara Biotherapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ATRAAtara Biotherapeutics | $86.2M | n/m | 4.6× | n/m | n/m | n/m | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Atara Biotherapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .